Exclusion of salary costs from research and development expenditure conflicts with IFRS UK pharmaceutical company Sinclair Pharma excludes salary costs from its research and development expenditure in treatment that conflicts with IFRS.
Presentation of a discontinued operation not fully in accordance with IFRS
UK pharmaceutical manufacturer ECO Animal Health(ECO) classifies an operation as discontinued but fails to present it in the income statement fully in accordance with the requirements under IFRS.
Reorganisation costs contribute to loss for the year
Following an acquisition, UK biotechnology company BTG recognises £10.9 million costs on reorganisation, that represents more than 96% of pre-tax loss.
